Dediabetes Logo
Preguntas
Respuestas publicadas conectadas con evidencia
Referencia clínica
Dossieres detallados de intervenciones y resultados
Investigacion reciente
Estudios mas recientes
Acerca de
Cómo funciona deDiabetes
Configuracion
Entrar / Unirse

Diabetic Kidney Disease: Evidence-Based Treatments and Outcomes

Ver informe de evidencia

Evidence related to diabetic kidney disease

Evidence related to diabetic kidney disease, albuminuria, kidney function, nephropathy progression, end-stage renal disease, and kidney-protective diabetes treatments.

Crea tu Evidence Workspace

Guarda evidencia sobre los temas que te importan.

14
Studies
16
Evidence Pairs
Moderate Research Support
Relationship Confidence: 67/100

Evidence guide

What does the evidence say?

Does Dapagliflozin lower Urinary albumin-to-creatinine ratio?

Dapagliflozin may lower Urinary albumin-to-creatinine ratio.

View answer

Does Empagliflozin lower Urinary albumin-to-creatinine ratio?

Empagliflozin may lower Urinary albumin-to-creatinine ratio.

View answer

Does Dapagliflozin improve Estimated glomerular filtration rate?

Dapagliflozin may improve Estimated glomerular filtration rate.

View answer
Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

Diabetic Kidney Disease evidence appears to center on Empagliflozin.

Among 14 indexed studies and 6 interventions, the strongest signals are summarized from the available evidence. Dapagliflozin has been studied often, while Empagliflozin appears to have stronger current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.
Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Empagliflozin appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies
Evidence basis: 8 evidence pairs - 9 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTsModerate evidence
Empagliflozin
4 studies
EvidenceScore™
78/100
ConsistencyScore™
82/100
Dapagliflozin
5 studies
EvidenceScore™
75/100
ConsistencyScore™
54/100

Evidence Snapshot

14
Studies
6
Interventions
7
Outcomes
1
Strong evidence signals
0
Mixed evidence areas

Key Findings

Key patterns and insights identified across the research landscape

Evidence signal

Empagliflozin shows evidence for Urinary albumin-to-creatinine ratio

Empagliflozin → Urinary albumin-to-creatinine ratio

Across 3 studies, Empagliflozin shows a consistent evidence signal for Urinary albumin-to-creatinine ratio.

3 studies
EvidenceScore™: 77.87179487179488/100
View supporting studies
Moderate positive signal

Dapagliflozin may improve Urinary albumin-to-creatinine ratio

Dapagliflozin → Urinary albumin-to-creatinine ratio

Across 4 studies, Dapagliflozin shows a consistent moderate positive signal for Urinary albumin-to-creatinine ratio.

4 studies
EvidenceScore™: 74.62065331928346/100
View supporting studies
Moderate positive signal

Dapagliflozin may improve Estimated glomerular filtration rate

Dapagliflozin → Estimated glomerular filtration rate

Across 2 studies, Dapagliflozin shows a moderate positive signal for Estimated glomerular filtration rate.

2 studies
EvidenceScore™: 69/100
View supporting studies
Neutral signal

Dapagliflozin shows limited or neutral effect on Serum CTX-1

Dapagliflozin → Serum CTX-1

Across 1 study, Dapagliflozin shows a neutral signal for Serum CTX-1.

1 studies
EvidenceScore™: 59/100
View supporting studies
Strong positive signal

Empagliflozin shows strong evidence for improving Estimated glomerular filtration rate

Empagliflozin → Estimated glomerular filtration rate

Across 1 study, Empagliflozin shows a strong positive signal for Estimated glomerular filtration rate.

1 studies
EvidenceScore™: 59/100
View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Dapagliflozin is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Dapagliflozin
Empagliflozin
Dapagliflozin
5 studies
EvidenceScore™
75/100
ConsistencyScore™
54/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results PresentNegative Results Present
Evidence basis: 15 evidence pairs - 13 studies
View supporting studies
Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Empagliflozin may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Empagliflozin
Pentoxifylline
Empagliflozin
4 studies
EvidenceScore™
78/100
ConsistencyScore™
82/100

Why this appears here

Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength
Evidence basis: 8 evidence pairs - 6 studies
View supporting studies

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Overall Evidence Signals

Among 14 indexed studies and 6 interventions, the strongest signals are summarized from the available evidence. Dapagliflozin has been studied often, while Empagliflozin appears to have stronger current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Evidence Relationships

Explore the intervention-outcome relationships with the strongest supporting evidence for Diabetic Kidney Disease.

1 strong relationship, ranked by available evidence

Select any relationship to review its supporting studies.

Continue exploring

Related evidence briefs

SGLT2 InhibitorsAdverse Events and Safety

Evidence Tracker

Track Diabetic Kidney Disease: Evidence-Based Treatments and Outcomes evidence

Save this evidence topic and revisit it as new studies are added.